Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Katsanos, Konstantinos H ^a   Briasoulis, Evangelos ^a   Tsekeris, Pericles ^a   Batistatou, Anna ^a   Bai, Maria ^a   Tolis, Christos ^a   Capizzello, Antonio ^a   Panelos, Ioannis ^a   Karavasilis, Vasileios ^a   Christodoulou, Dimitrios ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; EOSIN; HEMATOXYLIN; RADIOPROTECTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NAUSEA; NEUTROPENIA; PELVIS TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIGMOIDOSCOPY; STOMACH PROTECTION; TUMOR BIOPSY; VOMITING; ENDOMETRIUM TUMOR; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROSTATE TUMOR; RADIATION INJURY; RECTUM TUMOR; SURVIVAL RATE; UTERINE CERVIX TUMOR;

ADULT; AGED; AMIFOSTINE; COLITIS; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PELVIC NEOPLASMS; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RECTAL NEOPLASMS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 77953250972     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-68     Document Type: Article

References (35)

1. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. HJ Andreyev, Clin Oncol (R Coll Radiol) 2007 19 790 799 17904338
2. Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. FB Zimmermann HJ Feldmann, Strahlenther Onkol 1998 174 85 9 9830466
3. Mice's rectum radioprotection: comparative efficacy of a series of aminothiols and aminothiol precursors. C Schumacher K Paul Y Robbe MT Sicart JL Chanal R Delard JB Dubois, Farmaco 1997 52 729 31 9648277
4. Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis. A Keshavarzian J Haydek R Zabihi M Doria M D'Astice JR Sorenson, Dig Dis Sci 1992 37 1866 73 10.1007/BF01307573 1335406
5. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. H Athanassiou D Antonadou N Coliarakis A Kouveli M Synodinou M Paraskevaidis G Sarris GR Georgakopoulos K Panousaki P Karageorgis N Throuvalas Oncology Hellenic Group, Int J Radiat Oncol Biol Phys 2003 56 1154 60 10.1016/S0360-3016(03)00187-1 12829154
6. The natural history and management of radiation induced injury of the gastrointestinal tract. JJ DeCosse RS Rhodes WB Wentz JW Reagan HJ Dworken WD Holden, Ann Surg 1969 170 369 384 10.1097/00000658-196909010-00006 4979653
7. Acute radiation proctitis in man: development of eosinophilic crypt abscesses. MD Gelfand M Tepper LA Katz HJ Binder R Yesner MH Floch, Gastroenterology 1968 54 401 411 5643028
8. Radiation injury in surgical pathology: II. Alimentary tract. M Berthrong LF Fajardo, Am J Surg Pathol 1981 5 153 178 10.1097/00000478-198103000-00006 7013506
9. The light and electron microscopic features of early and late phase radiation-induced proctitis. NY Haboubi PF Schofield PL Rowland, Am J Gastroenterol 1998 83 1140 4
10. Severe radiation injuries of the stomach, small intestine, colon and rectum. B Roswit SJ Malsky CB Reid, Am J Roentgenol Radium Ther Nucl Med 1972 114 460 475 4622148
11. Variation between observers in describing mucosal appearances in proctocolitis. JH Baron AM Connel JE Lennard-Jones, Br Med J 1964 1 89 92 10.1136/bmj.1.5375.89 14075156
12. Expression of bcl2 family proteins and active caspace 3 in classical Hodgkin's lymphomas. M Bai A Papoudou-Bai N Horianopoulos C Grepi NJ Agnantis P Kanavaros, Hum Pathol 2007 38 103 13 10.1016/j.humpath.2006.06.017 16949642
13. Radiation induced pathology of the alimentary tract. LF Fajardo, Gastrointestinal and Esophageal Pathology Edinburgh: Churchill Livingstone, Whitehead R, 2 1995 957 965
14. Gastrointestinal Pathology. CM Fenoglio-Preiser, An Atlas and text Philadelphia: Lippincott-Raven 2 1999 816 820
15. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. MM Klingerman T Liu Y Liu B Scheffler S He Z Zhang, Int J Radiat Oncol Biol Phys 1992 22 799 802 1312078
16. Use of radiation with or without WR-2721 in advanced rectal cancer. T Liu Y Liu S He Z Zhang MM Kligerman, Cancer 1992 69 2820 2825 10.1002/1097- 0142(19920601)69:11<2820:AID-CNCR2820691130>3.0.CO;2-T 1315211
17. Radiation protection of murine intestine by WR-2721, 16,16-dimethyl prostaglandin E2, and the combination of both agents. WR Hanson, Rad Res 1987 111 361 73 10.2307/3576992 (Pubitemid 17156958)
18. WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment. TP Phan CH Crane NA Janjan E Vrdoljak L Milas KA Mason, Int J Pancreatol 2001 29 19 23 10.1385/IJGC:29:1:19 11558629
19. Topical application of WR-2721 achieves high concentrations in the rectal wall. E Ben-Josef J Mesina LM Shaw HS Bonner F Shamsa AT Porter, Radiat Res 1995 143 107 10 10.2307/3578933 7597137
20. Radioprotection of the rat small intestine with topical WR-2721. JP Delaney ME Bonsack I Felemovicius, Cancer 1994 74 2379 84 10.1002/1097- 0142(19941015)74:8<2379:AID-CNCR2820740825>3.0.CO;2-J 7922989
21. Protection by WR-2721 against radiation plus cis-diamminedichloroplatinum II caused injury to colonic epithelium in mice. H Ito R Komaki L Milas, Int J Radiat Oncol Biol Phys 1994 28 899 903 8138443
22. Intraoperative radiotherapy with localized radioprotection: diminished duodenal toxicity with intraluminal WR2721. FE Halberg SM LaRue AA Rayner WM Burnel BE Powers AS Chan MC Schell EL Gillette TL Phillips, Int J Radiat Oncol Biol Phys 1991 21 1241 6 1657841
23. Intracolonic WR 2721 protection of the rat colon from acute radiation injury. HG France Jr RL Jirtle CM Mansbach, Gastroenterology 1986 91 644 50 3015711
24. Protection of mouse jejunal crypt cells by WR-2721 after small doses of radiation. EL Travis HD Thames Jr SL Tucker TL Watkins I Kiss, Int J Radiat Oncol Biol Phys 1986 12 807 14 3011713
25. Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. JA van Laar CL van der Wilt M Treskes WJ van der Vijgh GJ Peters, Cancer Chemother Pharmacol 1992 31 97 102 10.1007/BF00685094 1333372
26. Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. CL van der Wilt JA van Laar F Gyergyay K Smid GJ Peters, Eur J Cancer 1992 28A 2017 24 10.1016/0959-8049(92) 90251-V 1329884
27. Enhanced tumour selectivity of photodynamic therapy in the rat colon using a radioprotective agent. J Bedwell PT Chatlani AJ MacRobert JE Roberts H Barr J Dillon SG Bown, Photochem Photobiol 1991 53 753 6 1653426
28. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial. GS Montana MS Anscher CM Mansbach M Delannes D Carke-Pearson EF Gaydica, Cancer 1992 69 2826 30 10.1002/1097- 0142(19920601)69:11<2826:AID-CNCR2820691131>3.0.CO;2-8 1315212
29. Evaluation of the possible benefits of post-radiotherapy surgery after concomitant chemoradiotherapy with a new radio-sensitizing regimen (irinotecan/CPT-11, interferon A2b and amifostine) for advanced-stage cervical carcinoma. Preliminary results of a pilot phase-II study. G Vorgias E Profitis G Sarris S Strigou C Kosmas M Katsoulis E Karamoussa N Kalinoglou N Koliarakis B Dertimas D Bafaloukos T Akrivos, J BUON 2009 14 197 202 19650166
30. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. O Nicolatou-Galitis A Sotiropoulou-Lontou A Velegraki G Pissakas G Kolitsi K Kyprianou V Kouloulias I Papanikolaou I Yiotakis K Dardoufas, Oral Oncol 2003 39 397 401 10.1016/S1368-8375(02)00144-6 12676261
31. Combined treatment with cytoprotective agents and radiotherapy. P Winczura J Jassem, Cancer Treat Rev 2009 20044209
32. The evolution and application of toxicity criteria. A Trotti, Sem Rad Oncol 2002 12 1 3 10.1053/srao.2002.31353
33. Transient P-cadherin expression in radiation proctitis; a model of mucosal injury and repair. RG Hardy RM Brown SJ Miller C Tselepis DG Morton JA Jankowski DS Sanders, J Pathol 2002 197 194 200 10.1002/path.1092 12015743
34. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. J Kouvaris V Kouloulias E Malas C Antypas J Kokakis S Michopoulos G Matsopoulos L Vlahos, Strahlenther Onkol 2003 179 167 74 10.1007/s00066-003-0970-y 12627259
35. Acute radiation colitis in patients treated with short-term preoperative radiotherapy for rectal cancer. N Leupin J Curschmann H Kranzbühler CA Maurer JA Laissue L Mazzucchelli, Am J Surg Pathol 2002 26 498 504 10.1097/00000478-200204000-00013 11914629